# OnCo record nct06617416 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06617416/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06617416", "NCT06617416" ;
  schema:name "A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC"@en ;
  schema:description "A phase 3 trial of Cadonilimab, Sugemalimab in non-small-cell lung cancer and small-cell lung cancer, run by Akeso, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06617416/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06617416> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2024-11-12" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/stage-iii-unresectable-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/cadonilimab/>, <https://onco.cc/drugs/sugemalimab/> ;
  onco:companies <https://onco.cc/companies/akeso/> .